We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-1.86%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$14.7B
AUM Growth
-$908M
Cap. Flow
-$379M
Cap. Flow %
-2.57%
Top 10 Hldgs %
84.38%
Holding
107
New
11
Increased
15
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$63.8M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$51.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$26M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$22.4M
5
HRTX icon
Heron Therapeutics
HRTX
+$20M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$184M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$97.2M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$69.5M
4
GHDX
Genomic Health, Inc.
GHDX
+$55.6M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.63%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$3.46B 23.55%
50,057,277
-992,483
-2% -$69.5M
INCY icon
2
Incyte
INCY
$25.5B
$2.72B 18.46%
31,976,193
-2,295,634
-7% -$184M
ONC
3
BeOne Medicines Ltd
ONC
$33.8B
$1.46B 9.92%
11,777,285
-182,539
-2% -$23.2M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$1.08B 7.35%
8,258,068
-300,000
-4% -$38.7M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$1.05B 7.14%
39,292,086
-421,756
-1% -$10.8M
AMRN
6
Amarin Corp
AMRN
$299M
$806M 5.47%
2,077,214
-83,309
-4% -$30.5M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12B
$650M 4.42%
7,589,294
– –
GHDX
8
DELISTED
Genomic Health, Inc.
GHDX
$539M 3.66%
9,260,922
-938,021
-9% -$55.6M
ASND icon
9
Ascendis Pharma A/S
ASND
$16.7B
$390M 2.65%
3,390,270
– –
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$259M 1.76%
2,513,462
– –
ARGX icon
11
argenx
ARGX
$55.1B
$144M 0.98%
1,019,557
– –
ARRY
12
DELISTED
Array Biopharma Inc
ARRY
$132M 0.9%
2,848,567
-993,722
-26% -$27.9M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.5B
$123M 0.83%
1,169,278
– –
NBIX icon
14
Neurocrine Biosciences
NBIX
$18.2B
$119M 0.81%
1,415,283
+316,613
+29% +$26M
HRTX icon
15
Heron Therapeutics
HRTX
$91.6M
$112M 0.76%
6,018,104
+1,000,000
+20% +$20M
KOD icon
16
Kodiak Sciences
KOD
$2.4B
$107M 0.73%
9,145,115
– –
NVTA
17
DELISTED
Invitae Corporation
NVTA
$91.7M 0.62%
3,902,421
– –
TCDA
18
DELISTED
Tricida, Inc. Common Stock
TCDA
$77.7M 0.53%
1,969,905
+166,667
+9% +$5.86M
ONCE
19
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$77M 0.52%
751,927
– –
BCEL
20
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$66.6M 0.45%
+3,532,760
New +$63.8M
GWPH
21
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$63.9M 0.43%
370,845
-57,500
-13% -$9.95M
INSM icon
22
Insmed
INSM
$22.7B
$63M 0.43%
2,462,216
+384,615
+19% +$10.7M
CERS icon
23
Cerus
CERS
$575M
$60.4M 0.41%
10,749,937
– –
RYTM icon
24
Rhythm Pharmaceuticals
RYTM
$7.33B
$59.6M 0.4%
2,708,200
– –
PRNB
25
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$59.3M 0.4%
1,787,807
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Baker Bros. Advisors held 107 positions worth $14.7B, down 5.8% from $15.6B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q2 2019 filing shows 11 new, 15 increased, 16 reduced and 4 closed positions. Its largest new stake was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M. The largest sale was Incyte, an estimated $184M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2019 buy was Atreca, Inc. Class A Common Stock: 3,532,760 shares worth $66.6M.
  • Baker Bros. Advisors added most to Neurocrine Biosciences in Q2 2019, an estimated $26M increase.
  • Baker Bros. Advisors's biggest Q2 2019 reduction was Incyte, cutting an estimated $184M.
  • Baker Bros. Advisors fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $97.2M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $14.7B portfolio in Q2 2019.
  • Baker Bros. Advisors opened 11 new positions and closed 4 in Q2 2019.
  • Baker Bros. Advisors's portfolio value fell 5.8% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.